Table 3. Competing Risk Models of Time Until Prostate Cancer–Specific Mortality and Distant Metastasis.
| Comparison | Subdistribution hazard ratio (95% CI)a | P value |
|---|---|---|
| All patients | ||
| Prostate cancer specific mortality | ||
| All EBRT vs all RP | 0.78 (0.63-0.97) | .03 |
| All EBRT+BT vs all RP | 0.70 (0.53-0.92) | .01 |
| All EBRT+BT vs all EBRT | 0.89 (0.67-1.18) | .43 |
| Distant metastasis | ||
| All EBRT vs all RP | 0.50 (0.44-0.58) | <.001 |
| All EBRT+BT vs all RP | 0.29 (0.23-0.36) | <.001 |
| All EBRT+BT vs all EBRT | 0.58 (0.46-0.73) | <.001 |
| Optimal treatment | ||
| Prostate cancer specific mortality | ||
| Optimal EBRT vs optimal RP | 0.76 (0.52-1.09) | .14 |
| Optimal EBRT+BT vs optimal RP | 0.86 (0.55-1.34) | .50 |
| Optimal EBRT+BT vs optimal EBRT | 1.13 (0.69-1.85) | .62 |
| Distant metastasis | ||
| Optimal EBRT vs optimal RP | 0.48 (0.38-0.61) | <.001 |
| Optimal EBRT+BT vs optimal RP | 0.25 (0.16-0.37) | <.001 |
| Optimal EBRT+BT vs optimal EBRT | 0.52 (0.33-0.80) | .003 |
Abbreviations: BT, brachytherapy boost; EBRT, external beam radiotherapy; RP, radical prostatectomy.
a
Models are adjusted with inverse probability of treatment weights. The factors in the model include treatment and age at treatment, natural log of initial prostate-specific antigen level, clinical T stage, and Gleason grade group.